Ocumension Therapeutics, a wholly owned subsidiary of Shanghai’s 6 Dimensions Capital, entered a $11.75 million deal for greater China rights to EyePoint Medical’s medical device that treats uveitis. The Durasert™ device is an insert that is effective for three years. It is aimed specifically at chronic, non-infectious posterior segment uveitis. Ocumension will pay $1.75 million upfront and up to $10 million in development, regulatory and sales milestones. Last month, EyePoint was approved to sell the device in the US.
Source: China Biotoday
